Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 01 04:00PM ET
1.67
Dollar change
-0.05
Percentage change
-2.91
%
Index- P/E- EPS (ttm)-6.21 Insider Own40.34% Shs Outstand2.08M Perf Week1.21%
Market Cap3.67M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float1.31M Perf Month38.02%
Income-13.04M PEG- EPS next Q-1.11 Inst Own5.30% Short Float21.56% Perf Quarter22.80%
Sales6.98M P/S0.53 EPS this Y- Inst Trans2.36% Short Ratio0.30 Perf Half Y-36.26%
Book/sh3.27 P/B0.51 EPS next Y- ROA-33.16% Short Interest0.28M Perf Year-16.50%
Cash/sh8.17 P/C0.20 EPS next 5Y- ROE-91.54% 52W Range0.92 - 9.54 Perf YTD18.44%
Dividend Est.- P/FCF- EPS past 5Y- ROI-90.21% 52W High-82.49% Beta2.28
Dividend TTM- Quick Ratio2.71 Sales past 5Y-17.34% Gross Margin17.66% 52W Low82.08% ATR (14)0.18
Dividend Ex-Date- Current Ratio3.02 EPS Y/Y TTM- Oper. Margin-140.66% RSI (14)62.45 Volatility8.82% 12.98%
Employees24 Debt/Eq1.23 Sales Y/Y TTM- Profit Margin-186.72% Recom1.00 Target Price4.00
Option/ShortNo / Yes LT Debt/Eq1.05 EPS Q/Q65.49% Payout- Rel Volume0.69 Prev Close1.72
Sales Surprise- EPS Surprise- Sales Q/Q214.88% Earnings- Avg Volume947.81K Price1.67
SMA2016.17% SMA5021.75% SMA200-18.36% Trades Volume656,501 Change-2.91%
Feb-14-24 09:15AM
Jan-24-24 09:15AM
Jan-17-24 09:00AM
Dec-12-23 10:00AM
09:15AM
09:15AM Loading…
Dec-05-23 09:15AM
Oct-30-23 09:15AM
Oct-19-23 09:00AM
Oct-04-23 09:00AM
Sep-28-23 08:00AM
Sep-11-23 09:00AM
Sep-06-23 04:05PM
Jul-13-23 04:30PM
Nov-30-22 12:45PM
Nov-15-22 08:00AM
09:00AM Loading…
Oct-25-22 09:00AM
Oct-21-22 08:00AM
Aug-15-22 08:00AM
Jul-28-22 10:27AM
09:25AM
Jul-19-22 09:15AM
May-16-22 05:00PM
May-03-22 09:23AM
Apr-27-22 09:25PM
09:00AM
Apr-26-22 09:15AM
Apr-19-22 09:15AM
Apr-01-22 07:00AM
Mar-03-22 08:00AM
Feb-01-22 09:15AM
09:15AM Loading…
Jan-24-22 09:15AM
Jan-18-22 09:20AM
Jan-06-22 04:30PM
Jan-05-22 01:38PM
Dec-28-21 09:15AM
Dec-22-21 09:10AM
Dec-08-21 09:15AM
Dec-02-21 12:00PM
Nov-30-21 09:00AM
Nov-15-21 04:30PM
Nov-11-21 09:15AM
Nov-08-21 09:15AM
Nov-03-21 09:16AM
Oct-21-21 09:25AM
Oct-19-21 09:25AM
Oct-14-21 09:00AM
Sep-23-21 08:30AM
Sep-10-21 08:30AM
Aug-17-21 09:25AM
Aug-16-21 08:30AM
Aug-12-21 08:00AM
Aug-11-21 10:39AM
Jul-27-21 09:25AM
Jul-13-21 09:15AM
Jul-12-21 08:15AM
Jun-02-21 10:12AM
May-17-21 08:22AM
May-14-21 08:30AM
May-07-21 08:00AM
Mar-18-21 09:00AM
Feb-18-21 08:00AM
Feb-04-21 08:30AM
Jan-19-21 08:00AM
Dec-08-20 04:15PM
Petros Pharmaceuticals, Inc. engages in men's health therapeutics. It is involved in sales, marketing, regulatory and medical affairs, finance, trade relations, pharmacovigilance, market access relations, manufacturing, and distribution. It operates through the Prescription Medications and Medical Devices segments. The Prescription Medications segment handles Stendra, a FDA approved PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction, and H100, a topical formulation candidate for the treatment of acute Peyronie's disease. The Medical Devices segment consists of vacuum erection devices. The company was founded on May 14, 2020 and is headquartered in New York, NY.